

Date: November 9, 2015

To: Valued Clients

From: Baylor Miraca Genetics Laboratories

RE: Test Discontinuation Memorandum

Effective December 9, 2015, Baylor Miraca Genetics Laboratories (BMGL) will discontinue the following test:

Test code 6084 – DMD Sequence Analysis

For alternative testing, we offer DMD Comprehensive Analysis by Next Generation Sequencing (test code 20145) that includes sequencing and copy number analysis, including female carrier analysis, and a Muscular Dystrophy Panel by Next Generation Sequencing (test code 24400) that contains the following genes:

ANO5, CAPN3, CAV3, DAG1, DES, DMD, DNAJB6, DPM3, DYSF, EMD, FHL1, FKRP, FKTN, GMPPB, ISPD, LMNA, MYH7, MYOT, PLEC, POMGNT1, POMT1, POMT2, PTRF, SGCA, SGCB, SGCD, SGCG, SMCHD1, SYNE1, SYNE2, TCAP, TMEM43, TNPO3, TRAPPC11, TRIM32, TTN

Please direct any billing questions to 713-798-3566 or email us at billing@bmgl.com. Please visit our website at www.BMGL.com for any additional notices or postings.

Thank you for your valued business. We look forward to providing you with the highest quality genetic testing services.

Sincerely,



Alan Pourpak, PhD, MBA
Director, Product Development and Strategy
Baylor Miraca Genetics Laboratories